提醒成功
微信/QQ登錄
搜索
首頁
| 產品規范 | |
|---|---|
| Type | In Vivo - Reseach Grade Antibody |
| Host | CHO cells |
| catalog# | B00060 |
| Application | Flow cytometry, animal model study |
| Aliases | Proprotein Convertase Subtilisin/Kexin Type 9 |
| Size/Concentration | 1mg/5mg/20mg |
| Isotype | Human IgG2 lambda |
| Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Human PCSK9 |
| Formulation | PBS, pH 7.4 |
Description |
|---|
What is evolocumab biosimilar research grade? Evolocumab (trade name Repatha) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. The PCSK9 protein targets LDL receptors for degradation. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR, in turn preventing PCSK9-mediated LDLR degradation and permitting the LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels. Evolocumab biosimilar uses the same protein sequences as the therapeutic antibody evolocumab. |
Evolocumab Biosimilar, Human PCSK9 Monoclonal Antibody B00060
聯系方式
CONTACT-
聯系電話:
0731-88388785 -
公司郵箱:
sales@promab.cn -
公司地址:
湖南省長沙市高新開發區林語路239號順暢產業園5樓
官方微信
產品中心
Product技術服務
service客戶留言
message